Kayothera

Kayothera

Biotechnology Research

Seattle, WA 355 followers

Drugging the Undruggable

About us

Kayothera specializes in inhibiting two of the last remaining nuclear receptors pathways to be drugged – the retinoid and rexinoid nuclear receptors. These pathways are clinically validated to drive adverse cardiometabolic and cancer outcomes, yet have no available inhibitors – until now. Kayothera’s unique approach blocks the formation of the retinoid or rexinoid nuclear ligands with novel, orally-available small molecules that have proven to be safe and effective medicines. We are developing these medicines to provide patients with new options for managing diabetes, obesity and cancer.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Seattle, WA
Type
Privately Held
Founded
2019

Locations

Employees at Kayothera

Updates

Similar pages

Browse jobs

Funding